The COMT Val158Met Polymorphism Is Associated with Response to Add-on Dextromethorphan Treatment in Bipolar Disorder

Sheng Yu Lee, Shiou Lan Chen, Tzu Yun Wang, Yun Hsuan Chang, Po See Chen, San Yuan Huang, Nian Sheng Tzeng, Liang Jen Wang, I. Hui Lee, Kao Ching Chen, Yen Kuang Yang, Ru Band Lu

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Purpose/Background We previously conducted a randomized, double-blind, controlled, 12-week study evaluating the effect of add-on dextromethorphan (DM), a noncompetitive N-methyl-d-aspartate receptor antagonist, on patients with bipolar disorder (BD) treated using valproate (VPA), which showed negative clinical differences. The genetic variation between each individual may be responsible for interindividual differences. The catechol-O-methyltransferase (COMT) gene has been a candidate gene for BD. In the current study, we investigated whether the COMT Val158Met polymorphism predicts treatment response to VPA + add-on DM and to VPA + placebo. Methods/Procedures Patients with BD (n = 309) undergoing regular VPA treatments were randomly assigned to groups given either add-on DM (30 mg/d) (n = 102), DM (60 mg/d) (n = 101), or placebo (n = 106) for 12 weeks. The Hamilton Depression Rating Scale and Young Mania Rating Scale were used to evaluate clinical response during weeks 0, 1, 2, 4, 8, and 12. The genotypes of the COMT Val158Met polymorphism were determined using polymerase chain reaction plus restriction fragment length polymorphism analysis. To adjust for within-subject dependence over repeated assessments, multiple linear regression with generalized estimating equation methods was used. Findings/Results When stratified by the COMT Val158Met genotypes, significantly greater decreases in Hamilton Depression Rating Scale scores were found in the VPA + DM (30 mg/d) group in patients with the Val/Met genotype (P = 0.008). Conclusions We conclude that the COMT Val158Met polymorphism may influence responses to DM (30 mg/d) by decreasing depressive symptoms in BD patients.

Original languageEnglish
Pages (from-to)94-98
Number of pages5
JournalJournal of Clinical Psychopharmacology
Issue number1
Publication statusPublished - 2017 Feb 1

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'The COMT Val158Met Polymorphism Is Associated with Response to Add-on Dextromethorphan Treatment in Bipolar Disorder'. Together they form a unique fingerprint.

Cite this